Welcome to Empower Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells, which are a type of B cell responsible for active immunity. Antibodies from myeloma cells can damage the kidneys, bone, and other organs.
Multiple myeloma is diagnosed in more than 34,000 patients each year and causes more than 12,000 deaths annually.1-3 Highly effective combinations of treatment are available for the management of multiple myeloma, which have improved clinical outcomes for patients over time.
These include proteasome inhibitors, immunomodulatory drugs (IMiDs), and corticosteroids. As a result, more and more patients are living longer. At the same time, advanced therapies have been developed including antibody therapies such as4-7:
- Signaling lymphocyte activation molecular family 7 (SLAMF7) antibodies
- Anti-CD38 antibodies
- B-cell maturation antigen (BCMA)-targeted antibody-drug conjugates
- Linvoseltamab (REGN5458)
- Alnuctamab (CC-93269)
- Elranatamab (PF-06863135)
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2023 Med Learning Group. Built by Divigner. All Rights Reserved.